BioArctic

BioArctic Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of BioArctic (BIOA B.ST) as of Nov 10, 2026 is -147.57. In the previous year, Cash Conversion Cycle (CCC) was -581.48 — a change of -74.62% (higher).

Cash Conversion Cycle

-147.57

YoY

-74.62%

Last updated:

Cash Conversion Cycle (CCC) of BioArctic is 2025 -147.57 . Cash Conversion Cycle (CCC) of BioArctic was 2024 -581.48 . It decreases by -74.62% higher compared to the previous year.

The BioArctic Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-1,198.08 SEK
Jan 1, 2019
-26.36 SEK
Jan 1, 2020
-103.97 SEK
Jan 1, 2021
-33.56 SEK
Jan 1, 2022
-68.72 SEK
Jan 1, 2023
-122.41 SEK
Jan 1, 2024
-581.48 SEK
Jan 1, 2025
-147.57 SEK
The BioArctic Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-147.57-74.62%
-581.48+375.03%
-122.41+78.12%
-68.72+104.75%
-33.56-67.72%
-103.97+294.38%
-26.36-97.80%
-1,198.08-81.71%
-6,550.79-65.47%
-18,968.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Cash Conversion Cycle (CCC) of BioArctic is -147.57 in 2025.

Cash Conversion Cycle (CCC) of BioArctic changed from -581.48 to -147.57, representing a -74.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) BioArctic since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioArctic

All Key Metrics — BioArctic